EGFR and non-small cell lung carcinoma: The survival rate of NSCLC patients is significantly increased under precision medicine guidance, for example, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) (erlotinib, gefitinib, and afatinib) have been successfully utilized in NSCLC patients with EGFR sensitive mutation4, 5.